Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509078 · ClinicalTrials.gov registry record · Phase 3
Reevaluation Of Systemic Early Neuromuscular Blockade
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,008
- Enrollment target
NCT02509078: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT02509078 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 1,008 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02509078, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,008 participants
- Enrollment target
Study Summary
This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a patient with acute respiratory distress syndrome will improve survival. Half of the patients will receive a neuromuscular blocker for two days and in the other half the use of neuromuscular blockers will be discouraged.
Interventions
- DRUG Cisatracurium Besylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,008 participants |
| Start Date | 2016-01-04 |
| Est. Completion | 2019-04-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02509078
The ClinicalTrials.gov registry entry for NCT02509078 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,008 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cisatracurium Besylate is the first listed.
NCT02509078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02509078 about?
NCT02509078 is a clinical study titled "Reevaluation Of Systemic Early Neuromuscular Blockade". This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a patient with acute respiratory distress syndrome will improve survival. Half of the patients will receive a neuromuscular blocker for two days and in the other half the use of neuromuscular blockers will be d...
What is the current status of trial NCT02509078?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,008 participants. The study started on 2016-01-04. Estimated completion is 2019-04-04.
What interventions are being tested in trial NCT02509078?
The interventions under investigation include: Cisatracurium Besylate (DRUG).
Who is sponsoring clinical trial NCT02509078?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.